Related Experiment Video
Updated: Jul 12, 2025

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Cancer-associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7
Joseph S Baxter1,2, Rachel Brough1,2, Dragomir B Krastev1,2
1The CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK.
Abstract:
The F-box and WD repeat domain containing 7 (FBXW7) tumour suppressor gene encodes a substrate-recognition subunit of Skp, cullin, F-box (SCF)-containing complexes. The tumour-suppressive role of FBXW7 is ascribed to its ability to drive ubiquitination and degradation of oncoproteins. Despite this molecular understanding, therapeutic approaches that target defective FBXW7 have not been identified. Using genome-wide clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 screens, focussed RNA-interference screens and whole and phospho-proteome mass spectrometry profiling in multiple FBXW7 wild-type and defective isogenic cell lines, we identified a number of FBXW7 synthetic lethal targets, including proteins involved in the response to replication fork stress and proteins involved in replication origin firing, such as cell division cycle 7-related protein kinase (CDC7) and its substrate, DNA replication complex GINS protein SLD5 (GINS4). The CDC7 synthetic lethal effect was confirmed using small-molecule inhibitors. Mechanistically, FBXW7/CDC7 synthetic lethality is dependent upon the replication factor telomere-associated protein RIF1 (RIF1), with RIF1 silencing reversing the FBXW7-selective effects of CDC7 inhibition. The delineation of FBXW7 synthetic lethal effects we describe here could serve as the starting point for subsequent drug discovery and/or development in this area.
Insights
Researchers identified CDC7 as a synthetic lethal target for defective FBXW7 tumor suppressor. This discovery, dependent on RIF1, offers a new avenue for cancer drug discovery targeting FBXW7-mutated cancers.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The FBXW7 tumor suppressor gene is crucial for degrading oncoproteins via the SCF complex.
- Defects in FBXW7 are linked to various cancers, but targeted therapies are lacking.
Purpose of the Study:
- To identify therapeutic targets synthetic lethal with FBXW7 loss.
- To elucidate the mechanism underlying FBXW7 synthetic lethality.
Main Methods:
- Genome-wide CRISPR-Cas9 and RNA-interference screens.
- Proteome and phospho-proteome mass spectrometry profiling.
- Validation using small-molecule inhibitors and RIF1 silencing.
Main Results:
- Identified CDC7 and GINS4 as FBXW7 synthetic lethal targets.
- Confirmed synthetic lethality of CDC7 inhibition in FBXW7-defective cells.
- Demonstrated RIF1 dependence of the FBXW7/CDC7 synthetic lethality.
Conclusions:
- FBXW7/CDC7 synthetic lethality is a promising therapeutic strategy for FBXW7-mutated cancers.
- RIF1 is a key mediator in this synthetic lethal interaction.
- The findings provide a foundation for developing novel cancer drugs.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Inhibition of Cdk Activity
Treatment Resistant Cancers

